VRL-1 CRISPR/Cas9 KO Plasmid (m): sc-423688
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- VRL-1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the VRL-1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VRL-1 CRISPR/Cas9 KO Plasmid (m) | sc-423688 | 20 µg | $397.00 |
Overview
Trpv2 encodes the mouse VRL-1 (TRPV2) channel, a nonselective cation channel of the transient receptor potential vanilloid family that contributes to stimulus-evoked Ca²⁺ influx. VRL-1 participates in cellular processes including mechanosensation and osmotic or thermal stress responses, and it can shape downstream calcium-dependent signaling that impacts membrane excitability, cytoskeletal dynamics, and transcriptional programs. In immune and myeloid lineages, TRPV2 activity has been linked to phagocytosis and inflammatory signaling, while in excitable tissues it is studied in the context of sensory transduction. Altered TRPV2 function or expression has been investigated in models of neuropathic pain, inflammatory disorders, cardiomyopathy, and cancer-related cell migration, supporting its relevance as a mechanistic target in diverse pathways.
VRL-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Trpv2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Trpv2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Trpv2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish VRL-1 protein expression.
This CRISPR knockout system enables efficient generation of Trpv2-deficient cell models for investigation of VRL-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Trpv2 exon(s) critical for VRL-1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Trpv2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by VRL-1 CRISPR/Cas9 KO Plasmid (m) and VRL-1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Trpv2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by VRL-1 HDR Plasmid (m) and VRL-1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Trpv2 homology arms to support homology-directed repair at defined Trpv2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.